Abeona Therapeutics Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter report; separate Q4 financial results are not provided in the supplied text.
Business context and progress
Abeona is a clinical-stage cell and gene therapy company with no significant product-sales revenue. Its lead candidate, prademagene zamikeracel (pz-cel), is an investigational autologous gene-corrected skin-cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). In 2023, the company submitted its BLA; the FDA accepted it for priority review and set a May 25, 2024 target action date. The pivotal VIITAL study met both co-primary endpoints for wound healing and pain reduction. Other programs, including ABO-503, ABO-504 and ABO-505, remained preclinical.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| License and other revenue | $3.5 million | $1.4 million |
| Research and development expense | $31.1 million | $29.0 million |
| General and administrative expense | $19.0 million | $17.3 million |
| Operating loss | $47.1 million | $50.9 million |
| Net loss | $54.2 million | $39.7 million |
| Net cash used in operating activities | $37.0 million | $43.5 million |
Revenue was primarily milestone-related income under the Taysha Rett syndrome sublicense, rather than product sales. Net loss widened mainly because the company recorded an $11.7 million non-cash loss from the change in fair value of warrant liabilities, compared with an $11.4 million gain in 2022. Loss per common share was $2.53 versus $5.53; the comparison also reflects a substantially higher weighted-average share count in 2023.
At year-end, cash, cash equivalents, restricted cash and short-term investments totaled $52.6 million. Current assets were $55.7 million and current liabilities were $13.4 million. Total liabilities were $49.2 million, including $31.4 million of warrant liabilities, $5.4 million of operating lease liabilities and a $4.6 million licensor settlement payable. The company reported an accumulated deficit of $749.5 million. No product gross margin was reported because the company had no significant product sales.
Operating cash use declined from 2022, while financing provided $37.1 million, including $14.4 million of ATM proceeds and $23.0 million net proceeds from a July 2023 direct placement. Shares issued and outstanding rose from 17.7 million at year-end 2022 to 26.5 million at year-end 2023. Management said available resources, together with subsequent financing, were expected to fund operations for at least 12 months from issuance of the financial statements.
Material changes, outlook and risks
- On January 8, 2024, Abeona entered a senior secured credit facility of up to $50 million. It received the $20 million first tranche; a further $10 million tranche is conditional on pz-cel approval and issuance of a priority review voucher, while an additional $20 million is discretionary to the lenders. The loans bear interest at the greater of prime plus 5% or 13.5%, are secured by substantially all assets, and include a $5 million minimum unrestricted-cash covenant.
- In March 2024, the FDA completed a pre-license inspection of the Cleveland manufacturing facility and issued a Form 483 with process-control observations. Abeona submitted a response on March 15, 2024. The FDA’s BIMO inspection and inspections of the two pivotal-trial sites had no Form 483 observations. The FDA indicated that an advisory committee and REMS were not anticipated at that stage; review remained ongoing.
- Management is preparing the Cleveland facility and treatment centers for a potential pz-cel launch and engaging with payors and providers. The filing gives no specific revenue, earnings or spending guidance and emphasizes that approval, commercialization and reimbursement are uncertain.
- Key risks include FDA review and resolution of manufacturing observations, the complexity and reliability of autologous manufacturing, dependence on external suppliers and service providers, limited cash runway and potential need for further financing, dilution, market access and reimbursement uncertainty, and competition. The company has a single manufacturing facility and states it has no backup manufacturer for pz-cel.
- Financial statements received an unqualified audit opinion. Management concluded internal control over financial reporting was effective; the auditor was not required to attest to that assessment. The filing reported no material pending litigation.
Important facts for investors to verify
- FDA’s pz-cel decision, any further review requests, and the status and resolution of the Cleveland facility Form 483 observations.
- Actual availability and conditions for the remaining credit-facility tranches, cash burn, covenant compliance and financing needs.
- Potential dilution from the ATM, outstanding warrants and other equity-linked securities; the filing lists 9.4 million liability-classified warrants outstanding at year-end.
- Whether pz-cel manufacturing can consistently meet release, scale and commercial-supply requirements, and whether approval and reimbursement would support viable commercialization.
- Timing and collectability of contingent sublicense milestones and royalties; these are not assured and are not included as recognized future revenue.